Christopher Downs
Known title: Chief Financial OfficerCIK: 0001705978
Christopher Downs's purchase track record
How the stock did after each of Christopher Downs's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
5
of 5 since November 19, 2021
Stock higher 6 months later
0%
3 months: 20%
Median 6-month return
-75.8%
3 months: -22.2%
Beat the S&P 500
0%
median -58.8% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/1/2024 | CNSP | $20K | -14.6% | -97.7% | +11.0% |
| 8/22/2023 | CNSP | $34K | +20.1% | -83.3% | +13.4% |
| 4/17/2023 | CNSP | $10K | -22.2% | -41.1% | +5.4% |
| 12/6/2021 | CNSP | $5K | -71.7% | -66.1% | -10.2% |
| 11/19/2021 | CNSP | $5K | -70.4% | -75.8% | -17.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CNSP | ▲ Buy | Open Market | 66,666 | $20K | 2/1/2024 | View on chart |
| CNSP | ▲ Buy | Open Market | 27,000 | $34K | 8/22/2023 | View on chart |
| CNSP | ▲ Buy | Option Exercise | 521 | — | 4/28/2023 | View on chart |
| CNSP | ▲ Buy | Open Market | 3,100 | $10K | 4/17/2023 | View on chart |
| CNSP | ▲ Buy | Grant | 33,000 | $10K | 3/11/2022 | View on chart |
| CNSP | ▲ Buy | Open Market | 5,000 | $5K | 12/6/2021 | View on chart |
| CNSP | ▲ Buy | Open Market | 4,500 | $5K | 11/19/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
CNS Pharmaceuticals Holds Shareholder/Analyst Call
On the call, CNS Pharmaceuticals shared recent developments and future plans. The session provided detailed updates for shareholders and analysts. The transcript offers insights into the company’s current focus and outlook.
CNS Pharmaceuticals Holds Shareholder/Analyst Call. On the call, CNS Pharmaceuticals shared recent developments and future plans. The session provided detailed updates for shareholders and analysts. The transcript offers insights into the company’s current focus and outlook.